17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04782830 (ClinicalTrials.gov)	February 5, 2021	1/3/2021	Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms	Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms	Orthostatic; Hypotension, Neurogenic;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy; Hypotension, Parkinsonism	Device: Accelerometer;Drug: placebo pill;Drug: Midodrine or atomoxetine pill	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	29	N/A	United States
2	NCT04620382 (ClinicalTrials.gov)	November 9, 2020	27/10/2020	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease	Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression	Vanderbilt University Medical Center	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	40 Years	80 Years	All	31	Early Phase 1	United States
3	NCT02897063 (ClinicalTrials.gov)	September 2016	7/9/2016	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2	Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension	Drug: Droxidopa;Drug: Midodrine;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	34	Phase 1	United States